Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec To Reduce Annual Operating Expenses By $200 Mil.-$300 Mil.

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen Idec’s strategic plan calls for divesting the psoriasis biologic Amevive (alefacept) and 17% workforce reductions, or 650 employees.

You may also be interested in...



Astellas Buys Amevive From Biogen Idec

Astellas will purchase Biogen Idec's psoriasis biologic Amevive (alefacept) for $60 mil. plus royalties

Astellas Buys Amevive From Biogen Idec

Astellas will purchase Biogen Idec's psoriasis biologic Amevive (alefacept) for $60 mil. plus royalties

Biogen Idec Business Development Plan Includes Small Molecules For Oncology

The company expects the bulk of expenditures from a $200 mil. business development plan will go toward up-front milestones and new clinical costs for in-licensed drugs.

Related Content

Topics

UsernamePublicRestriction

Register

PS063000

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel